Page last updated: 2024-12-06

be 2254

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BE 2254: produces blockade of central receptors for norepinephrine; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID34772
CHEMBL ID1515808
CHEBI ID91598
SCHEMBL ID6413372
MeSH IDM0056299

Synonyms (26)

Synonym
BRD-A24429032-003-01-6
be-2254
PDSP1_000832
PDSP2_000819
heat ,
NCGC00024637-02
be 2254
2-[[2-(4-hydroxyphenyl)ethylamino]methyl]-3,4-dihydro-2h-naphthalen-1-one
L000762
bdbm81809
cas_34772
nsc_34772
2-(beta-(4-hydroxyphenyl)ethylaminomethyl)tetralone
40077-13-2
2-heat
1(2h)-naphthalenone, 3,4-dihydro-2-(((2-(4-hydroxyphenyl)ethyl)amino)methyl)-
2-(((2-(4-hydroxyphenyl)ethyl)amino)methyl)-3,4-dihydro-1(2h)-naphthalenone
SCHEMBL6413372
CHEMBL1515808
CHEBI:91598
2-[beta-(4-hydroxyphenyl)ethylaminomethyl]tetralone
Q27163428
2-(((4-hydroxyphenethyl)amino)methyl)-3,4-dihydronaphthalen-1(2h)-one
2-({[2-(4-hydroxyphenyl)ethyl]amino}methyl)-3,4-dihydronaphthalen-1(2h)-one
DTXSID00960534
AKOS040747932

Research Excerpts

Overview

summarize : . IBE 2254 appears to be a very useful tool for studying alpha 1-adrenoceptors.

ExcerptReferenceRelevance
"IBE 2254 appears to be a very useful tool for studying alpha 1-adrenoceptors."( [125I]BE 2254, a new high affinity radioligand for alpha 1-adrenoceptors.
Engel, G; Hoyer, D, 1981
)
1.36

Dosage Studied

ExcerptRelevanceReference
" The reduction in alpha 1-adrenergic receptor density following phenoxybenzamine treatment was determined by Scatchard analysis of specific 125IBE binding sites and compared with the expected reduction (q values) calculated from the agonist dose-response curves before and after phenoxybenzamine treatment."( "Spare" alpha 1-adrenergic receptors and the potency of agonists in rat vas deferens.
Abel, PW; Minneman, KP, 1984
)
0.27
" Shifts in the (-)-noradrenaline dose-response curve produced by BE2254 and prazosin were parallel and there was no significant effect on the observed maximal response."( Competitive antagonism of alpha 1-adrenoceptor mediated pressor responses in the rat mesenteric artery.
Coupar, IM; McPherson, GA; Taylor, DA, 1984
)
0.27
" Dose-response studies demonstrate a higher potency and intrinsic activity of phenethylamines for polyphosphoinositide turnover but not for arachidonic acid release."( Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor.
Brown, F; Gaivin, R; Graham, RM; Hwa, J; Mathur, M; Perez, DM, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
tetralinsCompounds containing a tetralin skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency22.38725.623417.292931.6228AID485281
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency20.59620.000811.382244.6684AID686978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.95260.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency0.09470.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.94330.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency20.48090.354828.065989.1251AID504847; AID602199; AID602200; AID602201; AID602202
survival motor neuron protein isoform dHomo sapiens (human)Potency31.62280.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (131)

TimeframeStudies, This Drug (%)All Drugs %
pre-199080 (61.07)18.7374
1990's44 (33.59)18.2507
2000's4 (3.05)29.6817
2010's1 (0.76)24.3611
2020's2 (1.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.51 (24.57)
Research Supply Index4.91 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.74%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other134 (99.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]